AbbVie (ABBV)
Market Price (7/26/2026): $259.0 | Market Cap: $458.4 BilInvestor Relations Sector: Health Care | Industry: Biotechnology
AbbVie (ABBV)
Market Price (7/26/2026): $259.0Market Cap: $458.4 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 33% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 34%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 32%, CFO LTM is 21 Bil, FCF LTM is 20 Bil Attractive yieldDividend Yield is 2.6% Stock buyback supportStock Buyback 3Y Total is 4.2 Bil Low stock price volatilityVol 12M is 26% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Advanced Diagnostics, Show more. | Trading close to highsDist 52W High is 0.0%, Dist 3Y High is 0.0% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 52x, P/EPrice/Earnings or Price/(Net Income) is 126x Key risksABBV key risks include [1] the steep decline of Humira sales due to biosimilar competition, Show more. |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 33% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 34%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 32%, CFO LTM is 21 Bil, FCF LTM is 20 Bil |
| Attractive yieldDividend Yield is 2.6% |
| Stock buyback supportStock Buyback 3Y Total is 4.2 Bil |
| Low stock price volatilityVol 12M is 26% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Advanced Diagnostics, Show more. |
| Trading close to highsDist 52W High is 0.0%, Dist 3Y High is 0.0% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 52x, P/EPrice/Earnings or Price/(Net Income) is 126x |
| Key risksABBV key risks include [1] the steep decline of Humira sales due to biosimilar competition, Show more. |
Qualitative Assessment
AI Analysis | Feedback
AbbVie (ABBV) stock has gained about 20% since 3/31/2026 because of the following key factors:
1. Strategic Acquisition of Apogee Therapeutics Bolstered Immunology Portfolio.
AbbVie announced on June 22, 2026, an all-cash acquisition of Apogee Therapeutics for $10.9 billion, a move designed to significantly strengthen its immunology franchise for the next decade. This acquisition contributed to an approximate $43 billion increase in AbbVie's market value in the week leading up to June 30, with shares rising 6% on the news.
2. Strong Fiscal Q1 2026 Financial Results and Upgraded Full-Year Guidance.
AbbVie reported robust financial results for fiscal Q1 2026 (ending March 31, 2026), with revenues reaching $15 billion, surpassing Wall Street estimates by $300 million and demonstrating a 12% year-over-year growth. This growth was significantly driven by strong performances from immunology drugs Skyrizi, with sales up 29% operationally to $4.5 billion, and Rinvoq, which saw a 20% operational sales increase to $2.1 billion. Following these results, management raised its full-year 2026 revenue guidance to approximately $67.3 billion and its 2026 EPS guidance to $14.18, signaling 42% year-over-year growth and confidence in its diversified growth drivers.
Show more
AbbVie (ABBV) stock has gained about 20% since 3/31/2026 because of the following key factors:
1. Strategic Acquisition of Apogee Therapeutics Bolstered Immunology Portfolio.
AbbVie announced on June 22, 2026, an all-cash acquisition of Apogee Therapeutics for $10.9 billion, a move designed to significantly strengthen its immunology franchise for the next decade. This acquisition contributed to an approximate $43 billion increase in AbbVie's market value in the week leading up to June 30, with shares rising 6% on the news.
2. Strong Fiscal Q1 2026 Financial Results and Upgraded Full-Year Guidance.
AbbVie reported robust financial results for fiscal Q1 2026 (ending March 31, 2026), with revenues reaching $15 billion, surpassing Wall Street estimates by $300 million and demonstrating a 12% year-over-year growth. This growth was significantly driven by strong performances from immunology drugs Skyrizi, with sales up 29% operationally to $4.5 billion, and Rinvoq, which saw a 20% operational sales increase to $2.1 billion. Following these results, management raised its full-year 2026 revenue guidance to approximately $67.3 billion and its 2026 EPS guidance to $14.18, signaling 42% year-over-year growth and confidence in its diversified growth drivers.
3. Key Pipeline Advancements and Multiple Regulatory Approvals/Opinions.
The company experienced several positive developments in its pipeline. On June 29, 2026, AbbVie announced positive Phase 3 results for its EPCORE DLBCL-4 trial for epcoritamab, demonstrating a statistically significant improvement in progression-free survival for patients with relapsed or refractory diffuse large B-cell lymphoma, reducing the risk of disease progression and death by 60% and 56% respectively. Additionally, on June 29, 2026, AbbVie received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for upadacitinib (Rinvoq) for the treatment of severe alopecia areata and non-segmental vitiligo in adults and adolescents. Furthermore, on June 26, 2026, the FDA approved Skyrizi (risankizumab-rzaa) for pediatric patients aged six and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis, expanding its market reach.
4. Favorable Broader Life Sciences Market Trends.
The overall life sciences sector demonstrated optimism during fiscal Q2 2026, contributing to a positive environment for AbbVie. This was characterized by sustained momentum in manufacturing, consistent clinical trial activity, an increase in M&A activity, and new investments directed towards AI-enabled research. A notable reduction in biopharma layoffs also indicated improving financing conditions and a more stable industry outlook.
Show less
Stock Movement Drivers
Fundamental Drivers
The 21.1% change in ABBV stock from 3/31/2026 to 7/25/2026 was primarily driven by a 40.9% change in the company's P/E Multiple.| (LTM values as of) | 3312026 | 7252026 | Change |
|---|---|---|---|
| Stock Price ($) | 214.18 | 259.36 | 21.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 61,160 | 62,819 | 2.7% |
| Net Income Margin (%) | 6.9% | 5.8% | -16.3% |
| P/E Multiple | 89.7 | 126.3 | 40.9% |
| Shares Outstanding (Mil) | 1,769 | 1,770 | -0.1% |
| Cumulative Contribution | 21.1% |
Market Drivers
3/31/2026 to 7/25/2026| Return | Correlation | |
|---|---|---|
| ABBV | 21.1% | |
| Market (SPY) | 13.6% | -19.7% |
| Sector (XLV) | 10.9% | 68.3% |
Fundamental Drivers
The 16.2% change in ABBV stock from 12/31/2025 to 7/25/2026 was primarily driven by a 44.5% change in the company's Net Income Margin (%).| (LTM values as of) | 12312025 | 7252026 | Change |
|---|---|---|---|
| Stock Price ($) | 223.21 | 259.36 | 16.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 59,644 | 62,819 | 5.3% |
| Net Income Margin (%) | 4.0% | 5.8% | 44.5% |
| P/E Multiple | 165.4 | 126.3 | -23.6% |
| Shares Outstanding (Mil) | 1,769 | 1,770 | -0.1% |
| Cumulative Contribution | 16.2% |
Market Drivers
12/31/2025 to 7/25/2026| Return | Correlation | |
|---|---|---|
| ABBV | 16.2% | |
| Market (SPY) | 8.7% | -4.1% |
| Sector (XLV) | 5.5% | 60.1% |
Fundamental Drivers
The 45.3% change in ABBV stock from 6/30/2025 to 7/25/2026 was primarily driven by a 67.9% change in the company's P/E Multiple.| (LTM values as of) | 6302025 | 7252026 | Change |
|---|---|---|---|
| Stock Price ($) | 178.49 | 259.36 | 45.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 57,367 | 62,819 | 9.5% |
| Net Income Margin (%) | 7.3% | 5.8% | -20.9% |
| P/E Multiple | 75.2 | 126.3 | 67.9% |
| Shares Outstanding (Mil) | 1,768 | 1,770 | -0.1% |
| Cumulative Contribution | 45.3% |
Market Drivers
6/30/2025 to 7/25/2026| Return | Correlation | |
|---|---|---|
| ABBV | 45.3% | |
| Market (SPY) | 20.6% | -1.2% |
| Sector (XLV) | 22.2% | 60.4% |
Fundamental Drivers
The 115.9% change in ABBV stock from 6/30/2023 to 7/25/2026 was primarily driven by a 350.5% change in the company's P/E Multiple.| (LTM values as of) | 6302023 | 7252026 | Change |
|---|---|---|---|
| Stock Price ($) | 120.14 | 259.36 | 115.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 56,741 | 62,819 | 10.7% |
| Net Income Margin (%) | 13.4% | 5.8% | -56.7% |
| P/E Multiple | 28.0 | 126.3 | 350.5% |
| Shares Outstanding (Mil) | 1,770 | 1,770 | 0.0% |
| Cumulative Contribution | 115.9% |
Market Drivers
6/30/2023 to 7/25/2026| Return | Correlation | |
|---|---|---|
| ABBV | 115.9% | |
| Market (SPY) | 72.6% | 17.5% |
| Sector (XLV) | 28.2% | 59.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ABBV Return | 32% | 24% | -0% | 19% | 33% | 15% | 198% |
| Peers Return | 30% | 20% | -3% | 7% | 20% | 17% | 126% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 97% |
Monthly Win Rates [3] | |||||||
| ABBV Win Rate | 75% | 67% | 50% | 67% | 67% | 57% | |
| Peers Win Rate | 55% | 63% | 38% | 47% | 58% | 63% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 43% | |
Max Drawdowns [4] | |||||||
| ABBV Max Drawdown | -12% | -22% | -20% | -19% | -21% | -16% | |
| Peers Max Drawdown | -18% | -16% | -25% | -22% | -24% | -15% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: JNJ, PFE, MRK, BMY, LLY. See ABBV Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/24/2026 (YTD)
How Low Can It Go
| Event | ABBV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -13.0% | -18.8% |
| % Gain to Breakeven | 14.9% | 23.1% |
| Time to Breakeven | 11 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -13.0% | -6.7% |
| % Gain to Breakeven | 15.0% | 7.1% |
| Time to Breakeven | 30 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -31.5% | -33.7% |
| % Gain to Breakeven | 46.0% | 50.9% |
| Time to Breakeven | 59 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -18.0% | -19.2% |
| % Gain to Breakeven | 22.0% | 23.8% |
| Time to Breakeven | 412 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -12.3% | -3.7% |
| % Gain to Breakeven | 14.1% | 3.9% |
| Time to Breakeven | 10 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -29.8% | -12.2% |
| % Gain to Breakeven | 42.4% | 13.9% |
| Time to Breakeven | 284 days | 62 days |
In The Past
AbbVie's stock fell -13.0% during the 2025 US Tariff Shock. Such a loss loss requires a 14.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ABBV | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -31.5% | -33.7% |
| % Gain to Breakeven | 46.0% | 50.9% |
| Time to Breakeven | 59 days | 140 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -29.8% | -12.2% |
| % Gain to Breakeven | 42.4% | 13.9% |
| Time to Breakeven | 284 days | 62 days |
In The Past
AbbVie's stock fell -13.0% during the 2025 US Tariff Shock. Such a loss loss requires a 14.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About AbbVie (ABBV)
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and sale of advanced pharmaceutical products. The company focuses on addressing complex and serious health conditions through innovative therapies, operating across multiple therapeutic areas worldwide.
Its extensive product portfolio includes leading treatments in immunology, such as HUMIRA, SKYRIZI, and RINVOQ for autoimmune and inflammatory diseases like psoriasis and rheumatoid arthritis. In oncology, key products like IMBRUVICA and VENCLEXTA target various blood cancers. AbbVie also offers significant therapies for neuroscience (e.g., Ubrelvy for migraines, Duopa/Duodopa for Parkinson's disease), eye care (e.g., Lumigan/Ganfort, Alphagan for glaucoma, Restasis for dry eye), and virology (MAVYRET for hepatitis C). Other notable products include CREON for pancreatic insufficiency, Synthroid for hypothyroidism, and Lupron for conditions like prostate cancer and endometriosis.
AbbVie serves a diverse global market, providing its specialized medicines to patients through healthcare providers, hospitals, clinics, and pharmacies across numerous countries. Its primary customers are patients worldwide suffering from chronic and severe diseases, with therapies prescribed by a broad range of medical specialists including rheumatologists, oncologists, neurologists, and ophthalmologists, underscoring its focus on specialized and high-impact medical needs.
AI Analysis | Feedback
Like a diversified pharmaceutical giant, similar to Pfizer.
Like Johnson & Johnson, but purely focused on prescription drugs.
AI Analysis | Feedback
- HUMIRA: A therapy administered as an injection for autoimmune and intestinal Behçet's diseases.
- SKYRIZI: Treats moderate to severe plaque psoriasis in adults.
- RINVOQ: A JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis.
- IMBRUVICA: Treats adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
- VENCLEXTA: A BCL-2 inhibitor used to treat adults with CLL or SLL.
- MAVYRET: Treats patients with chronic HCV genotype 1-6 infection.
- CREON: A pancreatic enzyme therapy for exocrine pancreatic insufficiency.
- Synthroid: Used in the treatment of hypothyroidism.
- Linzess/Constella: Treats irritable bowel syndrome with constipation and chronic idiopathic constipation.
- Lupron: Used for advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids.
- Botox therapeutic: A therapeutic product with various medical applications.
- ORILISSA: A nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain.
- Duopa and Duodopa: A levodopa-carbidopa intestinal gel to treat Parkinson's disease.
- Lumigan/Ganfort: Reduces elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
- Ubrelvy: Treats migraine with or without aura in adults.
- Alphagan/Combigan: An alpha-adrenergic receptor agonist for the reduction of intraocular pressure in patients with open angle glaucoma.
- Restasis: A calcineurin inhibitor immunosuppressant to increase tear production.
AI Analysis | Feedback
AbbVie (ABBV) primarily sells its pharmaceutical products to other companies within the healthcare supply chain, rather than directly to individuals. Its major customers are pharmaceutical wholesalers and distributors, who then supply the drugs to pharmacies, hospitals, and other healthcare providers.
The principal customer companies are:
- AmerisourceBergen Corporation (NYSE: ABC)
- Cardinal Health, Inc. (NYSE: CAH)
- McKesson Corporation (NYSE: MCK)
AI Analysis | Feedback
AI Analysis | Feedback
Robert A. Michael, Chairman of the Board and Chief Executive Officer
Robert A. Michael was appointed Chief Executive Officer in 2024 and will assume the additional role of Chairman of the Board effective July 1, 2025. He has more than 30 years of experience, including leadership roles across pharmaceuticals, aesthetics, diagnostics, diabetes care, and nutrition. Prior to becoming CEO, Mr. Michael served as President and Chief Operating Officer of AbbVie. His previous roles at AbbVie also include Vice Chairman and President (2022), Vice Chairman, Finance and Commercial Operations (2021), and Chief Financial Officer (2018). Mr. Michael began his career with Abbott as a member of the financial development program and has been integral to AbbVie's success since its inception, including establishing its first financial planning organization and developing its diversified business strategy. Information regarding founding or managing other companies, selling companies they were previously involved with to an acquirer, or a pattern of managing companies backed by private equity firms is not available.
Scott T. Reents, Executive Vice President, Chief Financial Officer
Scott T. Reents was appointed Senior Vice President, Chief Financial Officer, effective June 23, 2022. He is responsible for the company's global financial operations. Mr. Reents joined Abbott in 2008 and has been with AbbVie since its separation in 2013. Prior to his current role, he served as Vice President, Tax and Treasury (2019-2022) and Vice President, Tax (2013-2019). Before joining Abbott, Mr. Reents worked in finance organizations at Pfizer and Pharmacia, and began his career at Deloitte. Information regarding founding or managing other companies, selling companies they were previously involved with to an acquirer, or a pattern of managing companies backed by private equity firms is not available.
Jeffrey R. Stewart, Executive Vice President, Chief Commercial Officer
Jeffrey R. Stewart serves as Executive Vice President, Chief Commercial Officer, a position he has held since his appointment in 2018. He leads the global commercial organization for AbbVie. Mr. Stewart joined Abbott in 1992 as part of TAP, a former U.S. joint venture with Takeda Chemical Industries. He held various leadership positions in Abbott's U.S. and international pharmaceutical businesses, including Divisional Vice President, Immunology; Divisional Vice President, Primary Care; General Manager, Virology; and General Manager, United Kingdom. Prior to AbbVie's separation from Abbott in 2013, he was Vice President, Abbott Proprietary Pharmaceutical Division, United States.
Azita Saleki-Gerhardt, Ph.D., Executive Vice President, Chief Operations Officer
Dr. Azita Saleki-Gerhardt is Executive Vice President, Chief Operations Officer, responsible for leading a global team in supply and distribution of all AbbVie products, as well as several enterprise services. She joined Abbott in 1993 as a research scientist and held key leadership positions in science and technology and quality assurance. In 2011, she became President, Global Pharmaceutical Operations at Abbott. Following AbbVie's spin-off from Abbott in 2013, Dr. Saleki-Gerhardt was appointed to lead Operations at AbbVie. She has significant experience in complex acquisitions and leading large international business operations.
Roopal Thakkar, M.D., Executive Vice President, Research & Development, Chief Scientific Officer
Dr. Roopal Thakkar was appointed Executive Vice President, Research & Development and Chief Scientific Officer in July 2024. He leads AbbVie's global R&D organization, which includes over 14,000 team members across all phases of discovery and development. A physician by training, Dr. Thakkar joined Abbott/AbbVie in 2003 and has held various positions in clinical development and regulatory affairs. His previous roles include Senior Vice President and Chief Medical Officer for Global Therapeutics, where he led strategic acquisitions and clinical development programs across multiple therapeutic areas.
```AI Analysis | Feedback
Key Risks to AbbVie (ABBV)
- Humira Biosimilar Erosion: The most significant risk to AbbVie's business is the ongoing and substantial decline in sales of its blockbuster drug, Humira, due to biosimilar competition. Humira's U.S. patent exclusivity ended in 2023, leading to multiple biosimilar launches. The company has experienced significant revenue decreases for Humira, with sales falling by nearly 50% in the first quarter of 2025 and 40% year-over-year in the first three months of 2024 in the U.S.. This "patent cliff" creates considerable margin pressure and necessitates a successful transition to next-generation immunology drugs like Skyrizi and Rinvoq to offset the revenue loss.
- Pipeline Challenges and Long-Term Growth Sustainability: While AbbVie's newer immunology drugs, Skyrizi and Rinvoq, are performing well and are expected to largely replace Humira's revenue, there are concerns about the perceived "lighter" late-stage pipeline compared to its biopharma peers. Many pipeline projects are focused on label expansions rather than entirely new drug approvals, raising questions about the company's ability to sustain long-term growth and find future blockbuster drugs beyond its current immunology and neuroscience portfolios.
- Regulatory and Pricing Pressures: AbbVie faces ongoing threats from evolving regulatory landscapes and market pressures, particularly concerning drug pricing. Cost-containment efforts by governments and private organizations, coupled with potential changes in healthcare policy, such as the Inflation Reduction Act in the U.S., could significantly impact the company's pricing power and revenue streams for its pharmaceutical products.
AI Analysis | Feedback
The entry of biosimilar versions of HUMIRA in the U.S. market represents a clear emerging threat to AbbVie's revenue and market share for its flagship product.
AI Analysis | Feedback
AbbVie (symbol: ABBV) operates in diverse pharmaceutical markets with several key products. The addressable market sizes for its main products or the therapeutic areas they target are detailed below:
- HUMIRA (adalimumab): Used for autoimmune and intestinal Behçet's diseases. The global Humira market size was valued at approximately USD 9.10 billion in 2024. However, due to patent expirations and the entry of biosimilars, the market for branded Humira is projected to decline to about USD 4.11 billion by 2030, with a CAGR of -11.29% from 2025 to 2030. The broader global autoimmune disease therapeutics market was valued at USD 168.6 billion in 2025 and is forecast to reach USD 226.2 billion by 2035. The global autoimmune disease diagnostics market, which indicates the scale of diagnosed patients, was estimated at USD 6.07 billion in 2025 and is projected to reach USD 9.58 billion by 2033.
- SKYRIZI: Treats moderate to severe plaque psoriasis in adults. The global psoriasis treatment market was estimated at USD 28.1 billion in 2024 and is expected to grow to USD 68.4 billion by 2034. Another source indicates the global psoriasis market size was valued at USD 31.68 billion in 2024 and is projected to reach USD 64.06 billion by 2032. North America accounted for the largest revenue share in the psoriasis treatment market in 2025.
- RINVOQ: A JAK inhibitor for moderate to severe active rheumatoid arthritis. The global rheumatoid arthritis therapeutics market size was estimated at USD 25.76 billion in 2024 and is projected to reach USD 41.42 billion by 2033. Another estimate valued the global rheumatoid arthritis drugs market at USD 60 billion, based on a five-year historical analysis. North America dominated the rheumatoid arthritis therapeutics market with the largest revenue share of 52.21% in 2024.
- IMBRUVICA / VENCLEXTA: These are used for conditions like chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Market sizes specific to these individual products or their direct addressable markets (CLL/SLL treatment market) were not explicitly found in the search results.
- MAVYRET: Treats chronic HCV genotype 1-6 infection. The global hepatitis C market size accounted for USD 7.95 billion in 2024 and is anticipated to reach around USD 10.62 billion by 2034. Another report valued the global hepatitis C market at USD 18.0 billion in 2023, expecting it to reach USD 47.1 billion by 2034. North America led the global market with the highest market share in 2024.
- CREON: A pancreatic enzyme therapy for exocrine pancreatic insufficiency (EPI). The global exocrine pancreatic insufficiency market size was valued at USD 3.2 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 6.6% from 2024 to 2030. Another source states the global exocrine pancreatic insufficiency therapeutics market size was USD 2.55 billion in 2026 and is projected to reach USD 3.51 billion by 2034. North America dominated the market in 2023.
- Synthroid: Used in the treatment of hypothyroidism. Market size information for Synthroid or the hypothyroidism treatment market was not explicitly found in the search results.
- Linzess/Constella: Treats irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Market size information for these products or their specific addressable markets was not explicitly found in the search results.
- Lupron: For the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. Market size information specific to Lupron or its diverse indications was not explicitly found in the search results.
- Botox therapeutic: The global botulinum toxin market, which includes therapeutic applications, was estimated at USD 13.2 billion in 2025 and is projected to reach USD 27.9 billion by 2033. Therapeutic applications held approximately 60% of the global market share in 2023. North America leads the global market, holding over 46.9% of the revenue share in 2023. The global therapeutic neurotoxin market size was valued at USD 6.34 billion in 2025 and is projected to reach USD 13.39 billion by 2034.
- ORILISSA: A nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. Market size information specific to Orilissa or the endometriosis pain market was not explicitly found in the search results.
- Duopa and Duodopa: Levodopa-carbidopa intestinal gel to treat Parkinson's disease. The global Parkinson's disease treatment market size was estimated at USD 5.65 billion in 2024 and is expected to reach USD 7.58 billion by 2030. Another source states the global Parkinson's disease drugs market size is likely to be valued at US$ 7.6 billion in 2025 and is estimated to reach US$ 13.3 billion in 2032. North America Parkinson's Disease Drugs Market is anticipated to account for approximately 45.6% of the share in 2025.
- Lumigan/Ganfort / Alphagan/Combigan: These ophthalmic solutions are for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension. Market size information for these specific products or the glaucoma/ocular hypertension market was not explicitly found in the search results.
- Ubrelvy: Treats migraine with or without aura in adults. The global migraine market size was valued at USD 3.95 billion in 2024 and is projected to reach USD 5.45 billion by 2032. Another estimate for the global migraine market size is expected to be worth around US$ 6.95 billion in 2024 and projected to reach US$ 18.86 billion by 2034. North America led the migraine market in 2024, achieving over 42.5% share. The migraine market across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) is poised to grow from $9.2 billion in 2023 to $16.4 billion in 2033.
- Restasis: A calcineurin inhibitor immunosuppressant to increase tear production (for dry eye). The global dry eye disease market size was estimated to be valued at USD 7.33 billion in 2024 and is expected to surpass USD 13.26 billion by 2031. Other estimates for the global dry eye syndrome treatment market size include USD 6.29 billion in 2024, projected to reach USD 9.20 billion by 2030, and USD 5.0 billion in 2024, expected to reach USD 8.0 billion by 2033. North America currently dominates the market, holding a significant market share of over 55.0% in 2024.
AI Analysis | Feedback
AbbVie (ABBV) anticipates several key drivers for future revenue growth over the next two to three years, building upon its diversified portfolio and pipeline investments.
Here are 5 expected drivers of AbbVie's future revenue growth:
- Strong Performance of Immunology Drugs (Skyrizi and Rinvoq): AbbVie expects its next-generation immunology drugs, Skyrizi and Rinvoq, to be the primary growth engines, significantly offsetting the impact of Humira's biosimilar erosion. These drugs are approved for major indications previously covered by Humira, as well as new areas like atopic dermatitis and inflammatory bowel disease. The combined sales of Skyrizi and Rinvoq are projected to exceed $31 billion in 2026, surpassing earlier long-term guidance.
- Growth in the Neuroscience Franchise: The neuroscience portfolio is poised for substantial expansion, with key products such as Vraylar, Botox Therapeutic, and the recently launched Vyalev. Vyalev is expected to achieve blockbuster status in 2026, contributing to the neuroscience franchise's anticipated global sales of $12.5 billion in the same year. Oral CGRP inhibitors like Ubrelvy and Qulipta, used for migraine treatment, are also forecast to surpass $5 billion in peak sales.
- Expansion and Development in Oncology: Despite near-term challenges for Imbruvica due to pricing changes from the Inflation Reduction Act, AbbVie is actively strengthening its oncology segment. The company's portfolio includes newer assets like Epkinly and Elahere, and it continues to invest in strategic acquisitions and pipeline developments, including bispecific antibodies and antibody-drug conjugates (ADCs). These efforts are expected to contribute multi-billion incremental revenue to the oncology franchise between 2026 and 2028.
- Rebound in the Aesthetics Business: The aesthetics segment, notably driven by products such as Botox, is anticipated to experience a rebound in sales. Management expects high single-digit growth for Botox Therapeutic sales in 2026, contributing positively to the company's overall revenue.
- Strategic Acquisitions and Robust Pipeline Investment: AbbVie's ongoing commitment to research and development (R&D) and opportunistic strategic acquisitions are crucial for long-term growth and diversification. The company has invested significantly in new business development, including platforms for CAR T therapy, next-generation psychedelics, novel trispecific antibodies, and treatments for obesity, ensuring a robust pipeline that extends growth beyond existing assets.
AI Analysis | Feedback
Share Repurchases
- AbbVie repurchased $1.6 billion in shares in 2023, $1.1 billion in 2022, and $1.3 billion in 2024.
- On February 16, 2023, AbbVie's board of directors authorized a $5.0 billion increase to the existing stock repurchase authorization, bringing the total authorization to $20.0 billion.
- The remaining stock repurchase authorization was $3.5 billion as of December 31, 2024.
Share Issuance
- AbbVie's shares outstanding were 1.773 billion in 2024, showing a 0% decline from 2023.
- The number of shares outstanding was 1,765,537 thousand in 2023, 1,767,880 thousand in 2022, and 1,767,880 thousand in 2021.
Outbound Investments
- AbbVie acquired ImmunoGen for $10.1 billion in February 2024 (agreement in November 2023) to strengthen its oncology portfolio and accelerate its entry into the ovarian cancer treatment market.
- The company acquired Cerevel Therapeutics for $8.7 billion in August 2024 (agreement in December 2023) to significantly strengthen its neuroscience pipeline.
- AbbVie acquired Capstan Therapeutics for approximately $2.1 billion in July 2025, adding a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy to its immunology pipeline and Capstan's proprietary tLNP platform technology.
Capital Expenditures
- AbbVie's capital expenditures were $1.214 billion in 2025, $974 million in 2024, $777 million in 2023, $695 million in 2022, and $787 million in 2021.
- The company made a significant investment in U.S. manufacturing capabilities.
- AbbVie announced in January 2026 a deal with the Trump administration to invest $100 billion in its U.S. operations over the next 10 years.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| How Does AbbVie Stock Stack Up Against Its Peers? | 07/09/2026 | |
| AbbVie Stock Traded Its Old Story for New Growth. Here Is The Price. | 07/08/2026 | |
| AbbVie Stock Surges 17%, With A 5-Day Winning Spree | 06/27/2026 | |
| AbbVie Stock And The Number Behind The Growth Story | 06/24/2026 | |
| Years of Rewards: $61 Bil From AbbVie Stock | 06/23/2026 | |
| AbbVie Stock's Real Strength Is How Little It Cares About the Market | 06/06/2026 | |
| AbbVie Earnings Notes | 04/28/2026 | |
| 5-Day Sell-Off Sends AbbVie Stock Down 7.5% | 03/24/2026 | |
| What Could Spark the Next Big Move In AbbVie Stock | 01/06/2026 | |
| How Low Can AbbVie Stock Really Go? | 01/06/2026 | |
| ARTICLES | ||
| AbbVie Stock Zigs When The Market Zags | 07/21/2026 | |
| ABBV Leads Its Peer Group. You Pay For That | 07/09/2026 | |
| AbbVie Stock Traded Its Old Story For New Growth. Here Is The Price. | 07/08/2026 | |
| S&P 500 Stocks Trading At 52-Week High | 07/03/2026 | |
| Stronger Bet Than AbbVie Stock: INCY Delivers More | 07/02/2026 |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 195.22 |
| Mkt Cap | 391.5 |
| Rev LTM | 64,541 |
| Op Inc LTM | 18,176 |
| FCF LTM | 13,012 |
| FCF 3Y Avg | 13,283 |
| CFO LTM | 19,185 |
| CFO 3Y Avg | 15,811 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.5% |
| Rev Chg 3Y Avg | 4.0% |
| Rev Chg Q | 6.0% |
| QoQ Delta Rev Chg LTM | 1.4% |
| Op Inc Chg LTM | 41.4% |
| Op Inc Chg 3Y Avg | 44.2% |
| Op Mgn LTM | 27.4% |
| Op Mgn 3Y Avg | 22.9% |
| QoQ Delta Op Mgn LTM | -0.2% |
| CFO/Rev LTM | 27.8% |
| CFO/Rev 3Y Avg | 27.7% |
| FCF/Rev LTM | 22.1% |
| FCF/Rev 3Y Avg | 21.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 391.5 |
| P/S | 5.7 |
| P/Op Inc | 23.1 |
| P/EBIT | 24.4 |
| P/E | 33.2 |
| P/CFO | 19.9 |
| Total Yield | 5.3% |
| Dividend Yield | 2.6% |
| FCF Yield 3Y Avg | 5.5% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 6.7% |
| 3M Rtn | 17.2% |
| 6M Rtn | 18.1% |
| 12M Rtn | 44.4% |
| 3Y Rtn | 50.3% |
| 1M Excs Rtn | 8.3% |
| 3M Excs Rtn | 10.7% |
| 6M Excs Rtn | 10.9% |
| 12M Excs Rtn | 29.0% |
| 3Y Excs Rtn | -3.9% |
Comparison Analyses
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA217906 | EMBLAVEO | avibactam sodium | powder | 2072025 | -2.3% | 5.8% | 21.2% | 42.8% | 42.8% |
| NDA216962 | VYALEV | foscarbidopa | solution | 10162024 | -9.2% | -8.2% | 23.3% | 44.3% | 44.3% |
| NDA218347 | RINVOQ LQ | upadacitinib | solution | 4262024 | 17.1% | 19.7% | 20.8% | 33.2% | 75.1% |
| NDA214028 | VUITY | pilocarpine hydrochloride | solution/drops | 10282021 | 25.3% | 45.2% | 39.8% | 36.9% | 180.7% |
| NDA215206 | QULIPTA | atogepant | tablet | 9282021 | 26.7% | 54.5% | 40.2% | 53.6% | 190.3% |
| NDA215110 | MAVYRET | glecaprevir | pellets | 6102021 | -6.7% | 9.3% | 28.5% | 28.8% | 171.1% |
| NDA213388 | ORIAHNN (COPACKAGED) | elagolix sodium,estradiol,norethindrone acetate | capsule | 5292020 | 2.9% | 16.1% | 28.3% | 77.3% | 257.2% |
| NDA211911 | DURYSTA | bimatoprost | implant | 3042020 | 0.5% | 5.2% | 21.3% | 80.9% | 266.2% |
| NDA211765 | UBRELVY | ubrogepant | tablet | 12232019 | -27.6% | 10.9% | 20.2% | 61.8% | 277.3% |
| NDA211675 | RINVOQ | upadacitinib | tablet, extended release | 8162019 | 39.6% | 50.1% | 55.9% | 100.4% | 436.2% |
| ... | |||||||||
| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA217906 | EMBLAVEO | avibactam sodium | powder | 2072025 | -2.3% | 5.8% | 21.2% | 42.8% | 42.8% |
| NDA216962 | VYALEV | foscarbidopa | solution | 10162024 | -9.2% | -8.2% | 23.3% | 44.3% | 44.3% |
| NDA218347 | RINVOQ LQ | upadacitinib | solution | 4262024 | 17.1% | 19.7% | 20.8% | 33.2% | 75.1% |
| NDA214028 | VUITY | pilocarpine hydrochloride | solution/drops | 10282021 | 25.3% | 45.2% | 39.8% | 36.9% | 180.7% |
| NDA215206 | QULIPTA | atogepant | tablet | 9282021 | 26.7% | 54.5% | 40.2% | 53.6% | 190.3% |
| NDA215110 | MAVYRET | glecaprevir | pellets | 6102021 | -6.7% | 9.3% | 28.5% | 28.8% | 171.1% |
| NDA213388 | ORIAHNN (COPACKAGED) | elagolix sodium,estradiol,norethindrone acetate | capsule | 5292020 | 2.9% | 16.1% | 28.3% | 77.3% | 257.2% |
| NDA211911 | DURYSTA | bimatoprost | implant | 3042020 | 0.5% | 5.2% | 21.3% | 80.9% | 266.2% |
| NDA211765 | UBRELVY | ubrogepant | tablet | 12232019 | -27.6% | 10.9% | 20.2% | 61.8% | 277.3% |
| NDA211675 | RINVOQ | upadacitinib | tablet, extended release | 8162019 | 39.6% | 50.1% | 55.9% | 100.4% | 436.2% |
| NDA210450 | ORILISSA | elagolix sodium | tablet | 7232018 | -4.7% | 2.4% | -20.3% | 21.5% | 306.7% |
| NDA209394 | MAVYRET | glecaprevir | tablet | 8032017 | 29.1% | 66.2% | 40.8% | 0.3% | 430.2% |
| NDA209512 | NORVIR | ritonavir | powder | 6072017 | 13.1% | 39.5% | 49.4% | 21.9% | 452.4% |
| NDA208624 | VIEKIRA XR | dasabuvir sodium | tablet, extended release | 7222016 | -3.6% | -2.3% | 21.5% | 49.8% | 512.7% |
| NDA206302 | BYVALSON | nebivolol hydrochloride | tablet | 6032016 | -0.5% | -6.9% | 7.5% | 62.0% | 506.8% |
| NDA208573 | VENCLEXTA | venetoclax | tablet | 4112016 | 11.1% | 10.2% | 15.0% | 71.8% | 580.7% |
| NDA204370 | VRAYLAR | cariprazine hydrochloride | capsule | 9172015 | -4.9% | -5.8% | 9.8% | 57.5% | 578.4% |
| NDA207931 | TECHNIVIE | ombitasvir | tablet | 7242015 | -25.4% | -11.9% | -2.6% | 18.3% | 496.5% |
| NDA206940 | VIBERZI | eluxadoline | tablet | 5272015 | -5.6% | -9.0% | -4.7% | 5.6% | 507.2% |
| NDA206333 | KYBELLA | deoxycholic acid | solution | 4292015 | 8.6% | -17.5% | -3.3% | 8.2% | 523.4% |
| NDA206494 | AVYCAZ | avibactam sodium | powder | 2252015 | 12.1% | 5.8% | -4.0% | 10.2% | 580.5% |
| NDA203952 | DUOPA | carbidopa | suspension | 1092015 | -5.0% | 6.9% | -12.6% | 4.0% | 531.8% |
| NDA206439 | NAMZARIC | donepezil hydrochloride | capsule, extended release | 12232014 | -6.6% | 10.5% | -6.0% | 2.8% | 545.8% |
| NDA206619 | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium | tablet | 12192014 | -10.1% | 4.2% | -15.0% | -1.4% | 513.8% |
| NDA021883 | DALVANCE | dalbavancin hydrochloride | powder | 5232014 | 3.1% | 26.7% | 25.2% | 18.3% | 682.0% |
| NDA204168 | FETZIMA | levomilnacipran hydrochloride | capsule, extended release | 7252013 | 9.3% | 12.3% | 24.3% | 64.0% | 878.5% |
| NDA204412 | DELZICOL | mesalamine | capsule, delayed release | 2012013 | 21.3% | 24.2% | 37.2% | 73.5% | 1,085.9% |
| NDA202211 | OXYTROL FOR WOMEN | oxybutynin | film, extended release | 1252013 | 23.0% | 21.3% | 31.7% | 77.5% | 1,072.6% |
| NDA202811 | LINZESS | linaclotide | capsule | 8302012 | |||||
| NDA021359 | RECTIV | nitroglycerin | ointment | 6212011 | |||||
| NDA022567 | VIIBRYD | vilazodone hydrochloride | tablet | 1212011 | |||||
| NDA200327 | TEFLARO | ceftaroline fosamil | powder | 10292010 | |||||
| NDA022184 | LUMIGAN | bimatoprost | solution/drops | 8312010 | |||||
| NDA022134 | LASTACAFT | alcaftadine | solution/drops | 7282010 | |||||
| NDA022525 | NAMENDA XR | memantine hydrochloride | capsule, extended release | 6212010 | |||||
| NDA022548 | ZYMAXID | gatifloxacin | solution/drops | 5182010 | |||||
| NDA022417 | NORVIR | ritonavir | tablet | 2102010 | |||||
| NDA022117 | SAPHRIS | asenapine maleate | tablet | 8132009 | |||||
| NDA022427 | ACUVAIL | ketorolac tromethamine | solution/drops | 7222009 | |||||
| NDA022315 | OZURDEX | dexamethasone | implant | 6172009 | |||||
| BLA020725 | CREON | pancrelipase (amylase | capsule, delayed release | 4302009 | |||||
| NDA022204 | GELNIQUE | oxybutynin chloride | gel | 1272009 | |||||
| NDA022256 | SAVELLA | milnacipran hydrochloride | tablet | 1142009 | |||||
| NDA022369 | LATISSE | bimatoprost | solution/drops | 12242008 | |||||
| NDA022224 | TRILIPIX | choline fenofibrate | capsule, delayed release | 12152008 | |||||
| NDA022206 | RAPAFLO | silodosin | capsule | 10082008 | |||||
| NDA021830 | ASACOL HD | mesalamine | tablet, delayed release | 5292008 | |||||
| NDA021398 | COMBIGAN | brimonidine tartrate | solution/drops | 10302007 | |||||
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Skyrizi | 17,562 | 11,718 | 7,763 | 5,165 | 2,939 |
| Rinvoq | 8,304 | 5,971 | 3,969 | 2,522 | 1,651 |
| Humira | 4,540 | 8,993 | 14,404 | 21,237 | 20,694 |
| Botox Therapeutic | 3,769 | 3,283 | 2,991 | 2,719 | 2,451 |
| Vraylar | 3,621 | 3,267 | 2,759 | 2,038 | 1,728 |
| Imbruvica | 2,869 | 3,347 | 3,596 | 4,568 | 5,408 |
| Venclexta | 2,792 | 2,583 | 2,288 | 2,009 | 1,820 |
| All other | 2,627 | 3,032 | 3,035 | 4,137 | 5,019 |
| Botox Cosmetic | 2,602 | 2,720 | 2,682 | 2,615 | 2,232 |
| Creon | 1,512 | 1,383 | 1,268 | 1,278 | 1,191 |
| Mavyret | 1,317 | 1,311 | 1,430 | 1,541 | 1,710 |
| Ubrelvy | 1,271 | 1,006 | 815 | 680 | 552 |
| Other Aesthetics | 1,265 | 1,279 | 1,234 | 1,290 | 1,466 |
| Qulipta | 1,036 | 658 | 408 | 158 | |
| Other Eye Care | 1,009 | 1,071 | 803 | 747 | 1,169 |
| Juvederm Collection | 993 | 1,177 | 1,378 | 1,428 | 1,535 |
| Linzess | 907 | 954 | 1,108 | 1,035 | 1,038 |
| Elahere | 690 | 479 | 0 | ||
| Ozurdex | 493 | 494 | 472 | 428 | |
| Vyalev | 482 | 99 | |||
| Lumigan/Ganfort | 410 | 429 | 432 | 514 | 579 |
| Duodopa | 381 | 447 | 468 | 458 | 511 |
| Epkinly | 271 | 146 | 31 | 0 | |
| Other Neuroscience | 207 | 239 | 276 | 475 | 685 |
| Alphagan/Combigan | 197 | 248 | 272 | 346 | 529 |
| Other Oncology | 33 | 0 | |||
| Restasis | 436 | 666 | 1,290 | ||
| Total | 61,160 | 56,334 | 54,318 | 58,054 | 56,197 |
Price Behavior
| Market Price | $259.36 | |
| Market Cap ($ Bil) | 459.1 | |
| First Trading Date | 01/02/2013 | |
| Distance from 52W High | 0.0% | |
| 50 Days | 200 Days | |
| DMA Price | $231.93 | $220.64 |
| DMA Trend | up | up |
| Distance from DMA | 11.8% | 17.5% |
| 3M | 1YR | |
| Volatility | 29.0% | 25.9% |
| Downside Capture | -167.05 | -31.39 |
| Upside Capture | -9.94 | 15.12 |
| Correlation (SPY) | -26.5% | -2.2% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.60 | -0.63 | -0.22 | -0.01 | 0.02 | 0.29 |
| Up Beta | -1.20 | -0.99 | 0.41 | 0.35 | 0.20 | 0.36 |
| Down Beta | 0.69 | 0.28 | -0.03 | -0.11 | -0.19 | 0.43 |
| Up Capture | -3% | -10% | -5% | 2% | 19% | 9% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 13 | 23 | 33 | 63 | 129 | 402 |
| Down Capture | -174% | -183% | -159% | -30% | -28% | 13% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 8 | 18 | 30 | 62 | 122 | 348 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ABBV | |
|---|---|---|---|---|
| ABBV | 40.5% | 25.8% | 1.28 | - |
| Sector ETF (XLV) | 20.9% | 15.7% | 1.02 | 59.3% |
| Equity (SPY) | 17.6% | 12.7% | 1.00 | -2.5% |
| Gold (GLD) | 19.2% | 28.1% | 0.61 | 0.6% |
| Commodities (DBC) | 34.7% | 19.1% | 1.42 | -17.5% |
| Real Estate (VNQ) | 13.8% | 14.1% | 0.69 | 31.1% |
| Bitcoin (BTCUSD) | -46.2% | 42.9% | -1.32 | -2.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ABBV | |
|---|---|---|---|---|
| ABBV | 21.6% | 23.4% | 0.80 | - |
| Sector ETF (XLV) | 6.4% | 15.0% | 0.25 | 58.1% |
| Equity (SPY) | 12.8% | 17.1% | 0.58 | 22.9% |
| Gold (GLD) | 17.0% | 18.4% | 0.75 | 2.3% |
| Commodities (DBC) | 9.6% | 19.5% | 0.38 | 3.5% |
| Real Estate (VNQ) | 3.0% | 18.9% | 0.06 | 29.7% |
| Bitcoin (BTCUSD) | 15.3% | 53.4% | 0.47 | -0.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ABBV | |
|---|---|---|---|---|
| ABBV | 19.9% | 25.9% | 0.72 | - |
| Sector ETF (XLV) | 10.0% | 16.6% | 0.49 | 63.4% |
| Equity (SPY) | 14.9% | 17.9% | 0.71 | 40.9% |
| Gold (GLD) | 11.3% | 16.1% | 0.57 | 0.7% |
| Commodities (DBC) | 7.2% | 17.9% | 0.32 | 12.3% |
| Real Estate (VNQ) | 5.2% | 20.7% | 0.21 | 35.6% |
| Bitcoin (BTCUSD) | 58.1% | 66.2% | 0.98 | 3.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 7/15/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/6/2026 | -0.0% | -2.7% | |
| 4/29/2026 | 3.1% | 4.3% | 10.6% |
| 2/4/2026 | -3.8% | -1.4% | 3.0% |
| 10/31/2025 | -4.5% | -4.0% | -1.7% |
| 7/31/2025 | -0.2% | 3.7% | 9.8% |
| 4/25/2025 | 3.2% | 7.2% | 1.6% |
| 1/31/2025 | 4.7% | 9.9% | 20.4% |
| 10/30/2024 | 6.4% | 6.5% | -3.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 13 | 14 | 16 |
| # Negative | 12 | 11 | 8 |
| Median Positive | 3.4% | 5.0% | 4.6% |
| Median Negative | -4.0% | -3.6% | -4.1% |
| Max Positive | 6.4% | 16.1% | 29.6% |
| Max Negative | -8.0% | -7.8% | -14.3% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/6/2026 | -0.0% | -2.7% | |
| 4/29/2026 | 3.1% | 4.3% | 10.6% |
| 2/4/2026 | -3.8% | -1.4% | 3.0% |
| 10/31/2025 | -4.5% | -4.0% | -1.7% |
| 7/31/2025 | -0.2% | 3.7% | 9.8% |
| 4/25/2025 | 3.2% | 7.2% | 1.6% |
| 1/31/2025 | 4.7% | 9.9% | 20.4% |
| 10/30/2024 | 6.4% | 6.5% | -3.4% |
| 7/25/2024 | 3.4% | 5.2% | 11.4% |
| 4/26/2024 | -4.6% | -3.9% | -6.1% |
| 2/2/2024 | 0.6% | 4.3% | 5.6% |
| 10/27/2023 | -4.3% | -1.3% | -4.2% |
| 7/27/2023 | 4.9% | 5.3% | 3.3% |
| 4/27/2023 | -8.0% | -7.8% | -14.3% |
| 2/9/2023 | 2.8% | 4.5% | 3.5% |
| 10/28/2022 | -3.8% | -5.9% | 3.2% |
| 7/29/2022 | -4.2% | -7.2% | -8.9% |
| 4/29/2022 | -6.0% | -2.6% | -4.0% |
| 2/2/2022 | 1.2% | 4.8% | 9.8% |
| 10/29/2021 | 4.6% | 6.7% | 6.6% |
| 7/30/2021 | -2.2% | -3.2% | 0.6% |
| 4/30/2021 | 0.6% | 4.7% | 2.1% |
| 2/3/2021 | 3.4% | 1.9% | 2.1% |
| 10/30/2020 | 5.5% | 16.1% | 29.6% |
| 7/31/2020 | -1.2% | -3.6% | -1.9% |
| SUMMARY STATS | |||
| # Positive | 13 | 14 | 16 |
| # Negative | 12 | 11 | 8 |
| Median Positive | 3.4% | 5.0% | 4.6% |
| Median Negative | -4.0% | -3.6% | -4.1% |
| Max Positive | 6.4% | 16.1% | 29.6% |
| Max Negative | -8.0% | -7.8% | -14.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/08/2026 | 10-Q |
| 12/31/2025 | 02/20/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/04/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 02/14/2025 | 10-K |
| 09/30/2024 | 11/04/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/03/2024 | 10-Q |
| 12/31/2023 | 02/20/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/05/2023 | 10-Q |
| 12/31/2022 | 02/17/2023 | 10-K |
| 09/30/2022 | 11/04/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/08/2026 | 10-Q |
| 12/31/2025 | 02/20/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/04/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 02/14/2025 | 10-K |
| 09/30/2024 | 11/04/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/03/2024 | 10-Q |
| 12/31/2023 | 02/20/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/05/2023 | 10-Q |
| 12/31/2022 | 02/17/2023 | 10-K |
| 09/30/2022 | 11/04/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/06/2022 | 10-Q |
| 12/31/2021 | 02/18/2022 | 10-K |
| 09/30/2021 | 11/02/2021 | 10-Q |
| 06/30/2021 | 08/02/2021 | 10-Q |
| 03/31/2021 | 05/07/2021 | 10-Q |
| 12/31/2020 | 02/19/2021 | 10-K |
| 09/30/2020 | 11/04/2020 | 10-Q |
| 06/30/2020 | 08/04/2020 | 10-Q |
| 03/31/2020 | 05/08/2020 | 10-Q |
| 12/31/2019 | 02/21/2020 | 10-K |
| 09/30/2019 | 11/06/2019 | 10-Q |
| 06/30/2019 | 08/05/2019 | 10-Q |
Recent Forward Guidance
Updated 7/8/2026Latest: Q2 2026 Earnings Reported 7/6/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Adjusted Diluted EPS | 13.9 | 14 | 14.1 | -1.2% | Lowered | Guidance: 14.2 for 2026 | |
| 2026 Acquired IPR&D and Milestones Expense | 1.03 Bil | ||||||
Prior: Q1 2026 Earnings Reported 4/29/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Adjusted Diluted EPS | 14.1 | 14.2 | 14.3 | 0.9% | Raised | Guidance: 14.5 for 2026 | |
Q4 2025 Earnings Reported 2/4/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Adjusted Diluted EPS | 14.4 | 14.5 | 14.6 | 36.1% | Higher New | Guidance: 10.6 for 2025 | |
Q3 2025 Earnings Reported 10/31/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Adjusted Diluted EPS | 10.6 | 10.6 | 10.7 | 1.4% | Raised | Guidance: 10.5 for 2025 | |
| 2026 Dividend Increase | 0.06 | ||||||
Insider Activity
Updated 7/2/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Purdue, David Ryan | SVP, Controller | Direct | Sell | 3062026 | 233.56 | 5,230 | 1,221,519 | 619,868 | Form |
| 2 | Siatis, Perry C | EVP, GC AND SECRETARY | Direct | Sell | 3032026 | 234.39 | 18,668 | 4,375,549 | 1,082,637 | Form |
| 3 | Siatis, Perry C | EVP, GC AND SECRETARY | Direct | Sell | 2272026 | 230.00 | 22,381 | 5,147,630 | 8,771,510 | Form |
| 4 | Saleki-Gerhardt, Azita | EVP, CHIEF OPERATIONS OFFICER | Direct | Sell | 8142025 | 198.42 | 42,370 | 8,407,055 | 35,178,279 | Form |
| 5 | Donoghoe, Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Direct | Sell | 8072025 | 198.51 | 13,295 | 2,639,253 | 11,562,738 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Purdue, David Ryan | SVP, Controller | Direct | Sell | 3062026 | 233.56 | 5,230 | 1,221,519 | 619,868 | Form |
| 2 | Siatis, Perry C | EVP, GC AND SECRETARY | Direct | Sell | 3032026 | 234.39 | 18,668 | 4,375,549 | 1,082,637 | Form |
| 3 | Siatis, Perry C | EVP, GC AND SECRETARY | Direct | Sell | 2272026 | 230.00 | 22,381 | 5,147,630 | 8,771,510 | Form |
| 4 | Saleki-Gerhardt, Azita | EVP, CHIEF OPERATIONS OFFICER | Direct | Sell | 8142025 | 198.42 | 42,370 | 8,407,055 | 35,178,279 | Form |
| 5 | Donoghoe, Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Direct | Sell | 8072025 | 198.51 | 13,295 | 2,639,253 | 11,562,738 | Form |
Investor Activity (13F)
Updated Jul 26, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Bruce & Co., Inc. | $26.6 Mil | 7.6% | 41 | Hold | 13F |
| Westchester Capital Management, Inc. | $22.5 Mil | 4.5% | 45 | Hold | 13F |
| Hamlin Capital Management, LLC | $181.9 Mil | 4.4% | 30 | TRIM -10.6% | 13F |
| Raub Brock Capital Management LP | $17.3 Mil | 4.4% | 43 | TRIM -11.0% | 13F |
| Brandywine Trust Co | $22.9 Mil | 4.1% | 31 | Hold | 13F |
| Atle Fund Management AB | $10.4 Mil | 3.4% | 39 | Hold | 13F |
| Cambridge Financial Group, Inc. | $8.1 Mil | 3.0% | 33 | Hold | 13F |
| Blackhill Capital Inc | $57.2 Mil | 2.9% | 49 | ADD +6.5% | 13F |
| Cincinnati Specialty Underwriters Insurance CO | $9.8 Mil | 2.4% | 46 | ADD +66.2% | 13F |
| Boothe Investment Group, Inc. | $6.7 Mil | 2.2% | 40 | Hold | 13F |
| Colrain Capital LLC | $5.4 Mil | 2.1% | 26 | ADD +16.5% | 13F |
| Legacy CG, LLC | $6.1 Mil | 1.7% | 45 | Hold | 13F |
| KCM Capital Inc | $7.6 Mil | 1.4% | 31 | Hold | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Hamlin Capital Management, LLC | $181.9 Mil | 4.4% | 30 | TRIM -10.6% | 13F |
| Blackhill Capital Inc | $57.2 Mil | 2.9% | 49 | ADD +6.5% | 13F |
| Bruce & Co., Inc. | $26.6 Mil | 7.6% | 41 | Hold | 13F |
| Brandywine Trust Co | $22.9 Mil | 4.1% | 31 | Hold | 13F |
| Westchester Capital Management, Inc. | $22.5 Mil | 4.5% | 45 | Hold | 13F |
| Raub Brock Capital Management LP | $17.3 Mil | 4.4% | 43 | TRIM -11.0% | 13F |
| Atle Fund Management AB | $10.4 Mil | 3.4% | 39 | Hold | 13F |
| Cincinnati Specialty Underwriters Insurance CO | $9.8 Mil | 2.4% | 46 | ADD +66.2% | 13F |
| Cambridge Financial Group, Inc. | $8.1 Mil | 3.0% | 33 | Hold | 13F |
| KCM Capital Inc | $7.6 Mil | 1.4% | 31 | Hold | 13F |
| Boothe Investment Group, Inc. | $6.7 Mil | 2.2% | 40 | Hold | 13F |
| Legacy CG, LLC | $6.1 Mil | 1.7% | 45 | Hold | 13F |
| Colrain Capital LLC | $5.4 Mil | 2.1% | 26 | ADD +16.5% | 13F |
ABBV Trade Sentinel
Constructive
CONVICTION RATIONALE
AbbVie's growth platform, led by Skyrizi and Rinvoq, is successfully driving accelerating revenue and significant margin expansion, more than offsetting legacy declines. While competition is intense and a recent guidance revision warrants caution, the core immunology franchise continues to gain market share, supported by strong clinical data and long-term patent protection.
STOCK ARCHETYPE
Patent-Protected FranchiseVolume (prescription growth and market share gains) x Net Price (negotiated with payers, subject to rebates and government price controls). Operating leverage driven by high-margin revenue growth from new products (Skyrizi, Rinvoq) outpacing growth in operating expenses.
INVESTMENT THESIS
Evidence suggests yes. The immunology franchise generated $25.9 billion in 2025, driving accelerating corporate revenue growth and substantial operating margin expansion.
- Skyrizi and Rinvoq 2025 combined sales were approximately $25.9 billion.
- Latest-quarter revenue growth accelerated to 12.4% year-over-year.
- TTM operating margin expanded by 10.7 percentage points to 33.2%.
- A legal settlement extends Rinvoq's U.S. market exclusivity to April 2037.
- Skyrizi holds a dominant 75% in-play capture rate in frontline IBD treatment.
PRIMARY RISK
Intensifying competition from rivals like Johnson & Johnson, whose competing drug grew 71%, could slow growth faster than expected. This risk is amplified by recent execution issues, including a key FDA rejection and a lowered full-year EPS guidance.
- Peer J&J's competing drug Tremfya grew sales 71% in its latest quarter.
- The FDA issued a complete response letter for a new toxin due to manufacturing issues.
- Full-year 2026 adjusted EPS guidance was recently lowered, with a new midpoint of $14.00.
- Legacy drug Imbruvica saw sales fall 24.7% due to competition and pricing.
| KPI | Status | Rationale |
|---|---|---|
| Skyrizi Global Sales Growth (Operational) | 29.2% operational growth in Q1 2026 - Decelerating | The deceleration in year-over-year growth is a natural function of the drug's increasing scale and larger sales base. Management attributes the growth to "continued strong market share uptake as well as market growth across all indications." The sequential decline is consistent with typical seasonality noted in prior guidance. |
| Rinvoq Global Sales Growth (Operational) | 20.2% operational growth in Q1 2026 - Decelerating | Similar to Skyrizi, Rinvoq's year-over-year growth is moderating as its sales base expands. Management attributes the growth to "continued strong market share uptake as well as market growth across all indications." The sequential decline reflects both seasonality and an unfavorable price comparison related to the timing of prior-year rebates. |
| Skyrizi In-Play Patient Share (U.S. Biologic Psoriasis Market) | More than 45% (Q4 2025) | Indicates Skyrizi's dominant position in capturing new and switching patients in its foundational market, reflecting strong physician preference. |
| Skyrizi In-Play Capture Rate (Frontline IBD) | Approximately 75% (Q4 2025) | Demonstrates Skyrizi's leadership in the fastest-growing part of the IBD market (new patient starts), signaling strong physician preference over competitors. |
| Rinvoq In-Play Patient Share (RA, U.S.) | Leading mid-teen share (Q4 2025) | Shows Rinvoq's strong competitive positioning in capturing new and switching rheumatoid arthritis patients, suggesting future total prescription share gains. |
New Portfolio Power vs. Execution Risk
BULL VIEW
The Skyrizi/Rinvoq platform is a durable engine, with combined 2025 sales of $25.9 billion already exceeding Humira's peak. Strong clinical data and long patent runways will sustain market share gains and drive high-margin growth for years.
CORE TENSION
Can accelerating revenue (12.4% last quarter) and expanding margins offset decelerating growth rates in key drugs and a recent cut to full-year EPS guidance?
PREVAILING SENTIMENT
The bull case holds for now. The last earnings report prompted a 7.0% stock rally, as the market focused on the revenue beat and then-raised guidance.
BEAR VIEW
Decelerating growth rates, a competitor growing at 71%, and a recent cut to EPS guidance suggest the transition is hitting a wall. The market may be underestimating the combined pressure of competition and execution stumbles.
| Timeline | Event & Metric To Watch |
|---|---|
Friday, July 31, 2026 | Second Quarter Earnings Call Watch: AbbVie to host its second-quarter 2026 earnings conference call. |
in the third quarter | Tavapadon Approval Decision Watch: Approval decision for tavapadon in Parkinson's disease is anticipated. |
in the third quarter | Myeloma Drug Trial Readout Watch: Response rate readout for monotherapy [indiscernible] in third-line plus multiple myeloma is anticipated. |
in the third quarter | Obesity Drug Phase II Start Watch: Phase II program for obesity asset is expected to begin. |
10/13/2026 | Immunology Competitive Read-Through Watch: JNJ's reported sales and management commentary for TREMFYA, specifically regarding market share trends in Crohn's disease and ulcerative colitis. |
10/29/2026 | Aesthetics Market Stagnation Watch: Management commentary on consumer sentiment and any revision to the full-year outlook for the Aesthetics portfolio. |
10/29/2026 | Legacy Drug Erosion Accelerates Watch: The rate of decline for Humira and Imbruvica sales versus expectations and its impact on total revenue growth. |
this summer | IBD Combo Trial Begins Watch: Phase IIb study in Crohn's disease and ulcerative colitis to evaluate Skyrizi in combination is planned to begin. |
in the second half of this year | Dermatology Drug Trial Readouts Watch: Top line results from Phase 3 studies for both Rinvoq and a recently discussed product in hidradenitis suppurativa are anticipated. |
later this year | Potential Oncology Drug Submission Watch: Regulatory submissions for [indiscernible] could occur if interim analysis is positive. |
| Date | Event | Stock Impact |
|---|---|---|
2026-07-17 | New Toxin Approved In Europe Details: Allergan Aesthetics received approval for Boey (trenibotulinumtoxinE) for use in Europe for the temporary improvement of frown lines in adult patients. | -0.4% $254.39 -> $253.38 |
2026-07-06 | Guidance Lowered For EPS Details: Company guidance for 2026 Adjusted Diluted EPS was lowered, with a new midpoint of 14, representing a change of -1.2%. | -2.5% $259.22 -> $252.85 |
2026-06-29 | Rinvoq EU Opinions Positive Details: Received positive CHMP opinions recommending approval for Rinvoq for the treatment of adults and adolescents with severe Alopecia Areata and non-segmental Vitiligo. | -0.7% $251.56 -> $249.86 |
2026-04-29 | First Quarter 2026 Results Details: Delivered Q1 net revenues of $15.002 billion, up 12.4%. The two-day stock reaction was 7.0%. | +6.9% $196.29 -> $209.83 |
2026-04-23 | US Toxin Application Rejected Details: The U.S. FDA issued a Complete Response Letter (CRL) for the TrenibotulinumtoxinE (TrenibotE) application, citing issues related to manufacturing processes. | -0.9% $199.08 -> $197.31 |
2026-03-02 | Positive Skyrizi Trial Results Details: Announced positive topline results from the Phase 3 AFFIRM study, where Skyrizi subcutaneous induction achieved superiority for co-primary and secondary endpoints in Crohn's disease. | +0.8% $228.54 -> $230.30 |
2026-02-20 | Venclexta Combination Approved Details: The U.S. FDA approved the combination treatment of Venclexta and Acalabrutinib for previously untreated patients with Chronic Lymphocytic Leukemia (CLL). | +2.3% $220.93 -> $225.98 |
2026-02-04 | Fourth Quarter 2025 Results Details: Company reported full-year 2025 net revenues of $61.160 billion, an increase of 8.6%, and adjusted diluted EPS of $10.00, a decrease of 1.2%. | -2.9% $222.22 -> $215.68 |
Position Sizing
5% - 7%
NORMAL POSITION
Sizing is volatility-based: ABBV trades at roughly 27% annualized options-implied volatility versus about 15% for the S&P 500 (1.8x the market), around the 71st percentile of its own trailing year. A 5% - 7% position keeps a single-name swing of that size within a diversified portfolio's risk budget.
Diversification Alternatives
JNJ - Johnson & Johnson
Diversified PeerJNJ offers greater diversification across MedTech and Consumer Health, reducing single-franchise risk. Its immunology drug Tremfya is growing faster, at 71% in the latest quarter.
LLY - Eli Lilly
Alternate Growth VectorLLY provides exposure to the high-growth obesity and diabetes markets, a different therapeutic area. It has superior revenue growth (47.4%) and operating margins (47.3%).
A post-Humira growth compounder, successfully swapping one blockbuster for a diversified portfolio led by a dominant immunology duo and a rapidly scaling neuroscience franchise.
AbbVie has successfully navigated its Humira patent cliff, with the combined force of Skyrizi and Rinvoq now far exceeding Humira's peak sales and driving top-tier growth. The company is leveraging its commercial and R&D prowess to build leadership positions in immunology and neuroscience, while investing in a deep pipeline in oncology and obesity to secure growth into the 2030s. The core investment thesis is a transition from a single-product story to a diversified, high-growth biopharma leader.
Continued market share gains for Skyrizi and Rinvoq, positive data from pipeline assets (especially oncology ADCs and obesity), and successful launches of new products like tavapadon.
Faster-than-expected erosion of key franchises due to new competition or pricing pressure, significant clinical trial failures in late-stage pipeline assets, or a prolonged downturn in the aesthetics market.
Quarterly fluctuations in aesthetics sales, minor patent litigation outside of core franchises.
Repricing Catalyst
Continued quarterly revenue and earnings beats driven by outperformance from Skyrizi and Rinvoq, leading to further guidance raises and increased investor confidence in the post-Humira growth trajectory. Positive readouts from the oncology and obesity pipelines are also key potential catalysts.
Neuroscience
$207M TTM (0% of Total)What It Is
Sells therapies for neurologic and psychiatric disorders, including Vraylar (schizophrenia, bipolar disorder), Botox Therapeutic (e.g., chronic migraine), Ubrelvy and Qulipta (migraine), and Vyalev/Duodopa (Parkinson's disease).
Who Pays & How
Payers reimburse for these treatments to manage debilitating neurological and psychiatric conditions. Physicians prescribe them for their efficacy and safety profiles in managing complex diseases.
Competition
Oncology
$33M TTM (0% of Total)What It Is
Sells therapies for blood cancers and solid tumors, including Imbruvica (ibrutinib) and Venclexta (venetoclax) for hematologic malignancies, and newer products like Elahere for ovarian cancer.
Who Pays & How
Payers reimburse for these often life-extending cancer treatments. Oncologists prescribe them based on efficacy in specific cancer types and patient profiles.
Competition
Aesthetics
$1.3B TTM (2% of Total)What It Is
Sells a portfolio of facial injectables, including Botox Cosmetic and the Juvederm Collection of dermal fillers, directly to physicians and other licensed healthcare providers for aesthetic procedures.
Who Pays & How
Consumers pay out-of-pocket for these elective cosmetic procedures to improve their appearance. Physicians and aesthetic practices purchase the products from AbbVie.
Competition
AbbVie — Investor Video Playlist
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.